Osimertinib After Amivantamab-Lazertinib–Associated Pneumonitis in EGFR-Mutant NSCLC: A Two-Case Report. // JTO Clinical and Research Reports. – URL: https://www.sciencedirect.com/science/article/pii/S266636432600113X?dgcid=rss_sd_all
Osimertinib After Amivantamab-Lazertinib–Associated Pneumonitis in EGFR-Mutant NSCLC: A Two-Case Report. JTO Clinical and Research Reports. https://www.sciencedirect.com/science/article/pii/S266636432600113X?dgcid=rss_sd_all
“Osimertinib After Amivantamab-Lazertinib–Associated Pneumonitis in EGFR-Mutant NSCLC: A Two-Case Report.” JTO Clinical and Research Reports.
@article{article98388,
title = {Osimertinib After Amivantamab-Lazertinib–Associated Pneumonitis in EGFR-Mutant NSCLC: A Two-Case Report},
journal = {JTO Clinical and Research Reports},
url = {https://www.sciencedirect.com/science/article/pii/S266636432600113X?dgcid=rss_sd_all}
}